Untitled Document

1479-0008

Beamion LUNG-2: A Phase III, open-label, randomized, activecontrolled, multi-centre trial evaluating orally administered BI 1810631 compared with standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic nonsquamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations

Cancer Types: Lung Cancer
Lines of Therapy: 1st Line Metastatic and Locally Advanced
More details: https://clinicaltrials.gov/study/NCT06151574?term=1479-0008&rank=1
Practices offering this clinical trial:

20180146

A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer

Cancer Types: Prostate Cancer
Lines of Therapy: Other
More details: https://clinicaltrials.gov/study/NCT04221542?term=20180146&rank=2
Practices offering this clinical trial:

20200041

A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects With Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305)

Cancer Types: Lung Cancer
Lines of Therapy: Other
More details: https://clinicaltrials.gov/study/NCT06211036?term=20200041&rank=1
Practices offering this clinical trial:

20210023

A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors

Cancer Types: Biliary Cancer, Bladder Cancer, Brain Cancer, Breast Cancer, Colon and Rectal Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, Melanoma, Ovarian and Endometrial Cancer, Pancreatic Cancer, Prostate Cancer
Lines of Therapy: Other
More details: https://clinicaltrials.gov/study/NCT05094336
Practices offering this clinical trial:

20210031

A Randomized, Double-blind Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 206 Compared with Opdivo (Nivolumab) in Subjects with Treatment-naïve Unrespectable or Metastatic Melanoma

Cancer Types: Melanoma
Lines of Therapy: 1st Line Metastatic and Locally Advanced
More details: https://clinicaltrials.gov/study/NCT05939219?term=20210031&rank=1
Practices offering this clinical trial:

21607

An Open Label, First-in-human Study of BAY 2927088 in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) Harboring an EGFR and/or HER2 Mutation

Cancer Types: Lung Cancer
Lines of Therapy: 2nd Line Metastatic, 3rd Line + Metastatic
More details: https://clinicaltrials.gov/study/NCT05099172?term=21607%20bay&checkSpell=false&rank=1
Practices offering this clinical trial:

221530 (JADE)

Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate Dostarlimab as Sequential Therapy After Chemoradiation in Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

Cancer Types: Head and Neck Cancer
Lines of Therapy: Adjuvant
More details: https://www.clinicaltrials.gov/study/NCT06256588
Practices offering this clinical trial:

54767414NAP4001 (HALO)

A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusion-related Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous)

Cancer Types: Multiple Myeloma
Lines of Therapy: Other
More details:
Practices offering this clinical trial:

61186372NS2012 COPERNICUS

A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Cancer Types: Lung Cancer
Lines of Therapy: 1st Line Metastatic and Locally Advanced, 2nd Line Metastatic
More details: https://clinicaltrials.gov/study/NCT06667076?term=61186372NSC2012&rank=1
Practices offering this clinical trial:

61186372NSC2007

A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivantamab + lazertinib

Cancer Types: Lung Cancer
Lines of Therapy: 1st Line Metastatic and Locally Advanced
More details: https://clinicaltrials.gov/study/NCT06120140?term=61186372nsc2007&rank=1
Practices offering this clinical trial:

849-001 (RM 615) KRYSTAL-1

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1

Cancer Types: Lung Cancer, Colon and Rectal Cancer, Pancreatic Cancer
Lines of Therapy: 2nd Line Metastatic, 3rd Line + Metastatic
More details: https://clinicaltrials.gov/ct2/show/NCT03785249?term=849-001&draw=2&rank=1
Practices offering this clinical trial:

A22-203

A Phase IIIb, Randomized, Open-Label, Parallel Group, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon Alfa-2b-njft (P1101) in Adult Patients With Polycythemia Vera (PV)

Cancer Types: Hematology and Blood Disorders
Lines of Therapy: Other
More details: https://www.clinicaltrials.gov/study/NCT05481151
Practices offering this clinical trial:

ACR-368-201

A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination With Gemcitabine in Adult Subjects With Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon OncoSignature® Status

Cancer Types: Ovarian and Endometrial Cancer
Lines of Therapy: 2nd Line Metastatic, 3rd Line + Metastatic
More details: https://clinicaltrials.gov/study/NCT05548296
Practices offering this clinical trial:

AK112-301 (LUN 515)

A Randomized, Double-blind, Multi-center, Phase III Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment

Cancer Types: Lung Cancer
Lines of Therapy: 1st Line Metastatic and Locally Advanced, 2nd Line Metastatic
More details: https://clinicaltrials.gov/study/NCT05184712?term=AK112-301&rank=1
Practices offering this clinical trial:

AK112-301 HARMONi

A Randomized, Double-blind, Multi-center, Phase III Study of AK112 or Placebo Combined with Pemetrexed and Carboplatin in Patients with EGFRmutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment

Cancer Types: Lung Cancer
Lines of Therapy: 2nd Line Metastatic, 3rd Line + Metastatic
More details: https://clinicaltrials.gov/study/NCT05184712?locStr=Bethesda,%20MD&country=United%20States&state=Maryland&city=Bethesda&term=AK112-301&rank=1
Practices offering this clinical trial:

ALKS 4230-007 (GYN 112) ARTISTRY-7

A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Cancer Types: Ovarian and Endometrial Cancer
Lines of Therapy: 2nd Line Metastatic, 3rd Line + Metastatic
More details: https://clinicaltrials.gov/ct2/show/NCT05092360?term=ALKS+4230-007&draw=2&rank=1
Practices offering this clinical trial:

AST-123.PN101

Double-blind, Placebo-controlled, Randomized, Dose-escalating, Multi-center, Phase 1 Study to Assess the Safety and Tolerability of ART-123 With Leucovorin/5-fluorouracil/Oxaliplatin and Bevacizumab in Metastatic Colorectal Cancer Patients

Cancer Types: Colon and Rectal Cancer
Lines of Therapy: 1st Line Metastatic and Locally Advanced
More details: https://clinicaltrials.gov/study/NCT05251727
Practices offering this clinical trial:

AZUR-2

A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy versus Standard of Care in Participants with Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Cancer Types: Colon and Rectal Cancer
Lines of Therapy: Neo-Adjuvant, Adjuvant
More details: https://clinicaltrials.gov/study/NCT05855200
Practices offering this clinical trial:

BC-IMT-04

A Phase III, Randomized, Open-label Study Comparing the Bria-IMT regimen in combination with Check Point Inhibitor vs Physician’s Choice in Metastatic Breast Cancer.

Cancer Types: Breast Cancer
Lines of Therapy: 3rd Line + Metastatic
More details: https://clinicaltrials.gov/search?locStr=Bethesda,%20MD&country=United%20States&state=Maryland&city=Bethesda&term=NCT06072612
Practices offering this clinical trial:

BGB-16673-101

Phase 1/2, Open-Label, Dose-Escalation and Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader, BGB-16673, in Patients With B-Cell Malignancies

Cancer Types: Lymphoma
Lines of Therapy: Other
More details: https://classic.clinicaltrials.gov/ct2/show/NCT05006716
Practices offering this clinical trial:

BGB-3111-308

A Phase 3, Open-Label Study of Zanubrutinib Plus Anti-CD20 Versus Rituximab and Lenalidomide (R2) in Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Cancer Types: Lymphoma
Lines of Therapy: Other
More details: https://clinicaltrials.gov/study/NCT05100862?cond=Follicular%20Lymphoma&term=BGB-3111-308&rank=1
Practices offering this clinical trial:

BNT327-01

Phase II, multi-site, open-label, parallel group study in participants with untreated extended-stage small-cell lung cancer (ES-SCLC) (Cohort 1) or small-cell lung cancer (SCLC) which has progressed on first- or second-line treatment (Cohort 2 and Cohort 3). This study will assess the safety, efficacy, and pharmacokinetics (PK) of BNT327.

Cancer Types: Lung Cancer
Lines of Therapy: 1st Line Metastatic and Locally Advanced
More details: https://clinicaltrials.gov/study/NCT06449209
Practices offering this clinical trial:

BNT327-03

Phase III, multisite, randomized, double-blinded study to investigate BNT327 combined with chemotherapy (etoposide/carboplatin) compared to atezolizumab combined with chemotherapy (etoposide/carboplatin) for the treatment of participants with previously untreated extensive-stage small-cell lung cancer (ES-SCLC).

Cancer Types: Lung Cancer
Lines of Therapy: 1st Line Metastatic and Locally Advanced
More details: https://clinicaltrials.gov/study/NCT06712355
Practices offering this clinical trial:

Bo44157 (GU 220)

A Phase II, Randomized, Multicenter, Open-Label, Controlled Study of RO7247669 Alone or in Combination With Tiragolumab Versus Atezolizumab in Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer Who Are Ineligible for Platinum-Containing Chemotherapy

Cancer Types: Bladder Cancer
Lines of Therapy: 1st Line Metastatic and Locally Advanced
More details: https://clinicaltrials.gov/ct2/show/NCT05645692
Practices offering this clinical trial:

C1071007 MagnetisMM-7

A RANDOMIZED, 2-ARM, PHASE 3 STUDY OF ELRANATAMAB (PF-06863135) VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEM-CELL TRANSPLANTATION

Cancer Types: Multiple Myeloma
Lines of Therapy: Other
More details: https://clinicaltrials.gov/study/NCT05317416?term=c1071007&rank=1
Practices offering this clinical trial:

CA056-025

A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate-Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-Naive Participants Who Are Non-Transfusion Dependent (NTD): The "ELEMENT-MDS" Trial

Cancer Types: Hematology and Blood Disorders
Lines of Therapy: Other
More details: https://clinicaltrials.gov/study/NCT05949684?term=ca056-025&rank=1
Practices offering this clinical trial:

CC-220-MM-002 Excaliber-RRMM

A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM)

Cancer Types: Hematology and Blood Disorders
Lines of Therapy: Other
More details: https://clinicaltrials.gov/study/NCT04975997
Practices offering this clinical trial:

CELC-G-301 VIKTORIA-1

Phase 3, Open-Label, Randomized, Study Comparing Gedatolisib Combined With Fulvestrant & With or Without Palbociclib to Standard-of-Care Therapies in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination w/Non-Steroidal Aromatase Inhibitor Therapy

Cancer Types: Breast Cancer
Lines of Therapy: 2nd Line Metastatic, 3rd Line + Metastatic
More details: https://clinicaltrials.gov/study/NCT05501886
Practices offering this clinical trial:

CELC-G-302

A Randomized, Open-Label, Phase 3 Study of Fulvestrant and CDK4/6 Inhibitors With or Without Gedatolisib as First-Line Treatment in Patients With HR-Positive and HER2-Negative Advanced Breast Cancer

Cancer Types: Breast Cancer
Lines of Therapy: 1st Line Metastatic and Locally Advanced
More details: https://clinicaltrials.gov/study/NCT06757634?term=celc-g-302&rank=1
Practices offering this clinical trial:

CRDF-004

Phase 2, Randomized, Open-label Study of Onvansertib in Combination with FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-line Treatment of Metastatic Colorectal Cancer in Patients with a KRAS or NRAS Mutation

Cancer Types: Colon and Rectal Cancer
Lines of Therapy: 1st Line Metastatic and Locally Advanced
More details: https://clinicaltrials.gov/study/NCT06106308
Practices offering this clinical trial:

CVAY736I12301

A Phase III, Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (VAYHIT1)

Cancer Types: Hematology and Blood Disorders
Lines of Therapy: Other
More details: https://clinicaltrials.gov/study/NCT05653349?term=CVAY736I12301&rank=1
Practices offering this clinical trial:

D361DC00001 Capitello-292

Phase Ib/III Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)

Cancer Types: Breast Cancer
Lines of Therapy: 2nd Line Metastatic
More details: https://clinicaltrials.gov/study/NCT04862663
Practices offering this clinical trial:

D419ML00003 TRITON

A Phase IIIb, Randomized, Multicenter, Open-lable Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Bases Chemotherapy for First-Line Treatment in Metastatic No-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutation in STK11, KEAP1 or KRAS.

Cancer Types: Lung Cancer
Lines of Therapy: 1st Line Metastatic and Locally Advanced
More details: https://clinicaltrials.gov/study/NCT06008093?locStr=Bethesda,%20MD&country=United%20States&state=Maryland&city=Bethesda&cond=Non-small%20Cell%20Lung%20Cancer&intr=Durvalumab,Tremelimumab&rank=1
Practices offering this clinical trial:

D533BC00001 LATIFY

A Phase III, Open-label, Randomised, Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations, and Whose Disease Has Progressed On or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy

Cancer Types: Lung Cancer
Lines of Therapy: 2nd Line Metastatic
More details: https://classic.clinicaltrials.gov/ct2/show/NCT05450692?term=D533BC00001&draw=2&rank=1
Practices offering this clinical trial:

D8531C00002 (BRE 405) CAMBRIA-1

A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast Cancer

Cancer Types: Breast Cancer
Lines of Therapy: Adjuvant
More details: https://clinicaltrials.gov/study/NCT05774951?term=D8531C00002&rank=1
Practices offering this clinical trial:

D8535C00001 CAMBRIA-2

A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease

Cancer Types: Breast Cancer
Lines of Therapy: Adjuvant
More details: https://clinicaltrials.gov/study/NCT05952557?term=D8535C00001&rank=1
Practices offering this clinical trial:

D926NC00001 (LUN 512) AVANZAR

A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations

Cancer Types: Lung Cancer
Lines of Therapy: 1st Line Metastatic and Locally Advanced
More details: https://clinicaltrials.gov/study/NCT05687266?term=D926NC00001&rank=1
Practices offering this clinical trial:

D926XC00001 (BRE 409) TROPION-Breast03

A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (DatoDXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)

Cancer Types: Breast Cancer
Lines of Therapy: Adjuvant
More details: https://clinicaltrials.gov/study/NCT05629585?term=D926XC00001&rank=1
Practices offering this clinical trial:

D9273C00001 (EvoPAR-Prostate01)

Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of Saruparib (AZD5305) in Combination With Physician's Choice New Hormonal Agents in Patients With HRRm and Non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01)

Cancer Types: Prostate Cancer
Lines of Therapy: 1st Line Metastatic and Locally Advanced
More details: https://clinicaltrials.gov/study/NCT06120491
Practices offering this clinical trial:

DC15-MM-1

A Phase 1 Dose-Escalation and Expansion study of Descartes-15, a BCMA-targeting RNA-engineered CAR T-cell therapy, in patients with Relapsed or Refractory MM

Cancer Types: Hematology and Blood Disorders
Lines of Therapy: Other
More details: https://clinicaltrials.gov/study/NCT06304636?term=descartes-15&rank=1
Practices offering this clinical trial:

DCL-16-001 CLOVER-WaM

An Open-Label, Multicenter, Phase 2 Study of Iopofosine I 131 (CLR 131) in Patients With Relapsed or Refractory (R/R) Select B-Cell Malignancies (CLOVER-1) and Expansion Cohort in Patients With Waldenstrom Macroglobulinemia

Cancer Types: Hematology and Blood Disorders, Lymphoma
Lines of Therapy: Other
More details: https://clinicaltrials.gov/study/NCT02952508
Practices offering this clinical trial:

DS102A-10-RD2

An Open-label Mechanistic Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Orally Administered Epeleuton in Patients With Sickle Cell Disease

Cancer Types: Hematology and Blood Disorders
Lines of Therapy: Other
More details: https://clinicaltrials.gov/study/NCT05861453?term=DS102A-10-RD2&rank=1
Practices offering this clinical trial:

DS1062-A-U303 TROPION-Lung07

A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in Subjects With No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations

Cancer Types: Lung Cancer
Lines of Therapy: 1st Line Metastatic and Locally Advanced
More details: https://clinicaltrials.gov/study/NCT05555732
Practices offering this clinical trial:

DS1062-A-U304 TROPION-Lung08

A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects With Advanced or Metastatic PD-L1 High (TPS ≥50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)

Cancer Types: Lung Cancer
Lines of Therapy: 1st Line Metastatic and Locally Advanced
More details: https://clinicaltrials.gov/study/NCT05215340
Practices offering this clinical trial:

DS8201-A-U106

A Phase 1b, Multicenter, Two-Part, Open-Label Study of Trastuzumab Deruxtecan (DS-8201a), An Anti-Human Epidermal Growth Factor Receptor-2 (HER2)-Antibody Drug Conjugate (ADC), In Combination With Pembrolizumab, An Anti-PD-1 Antibody, For Subjects With Locally Advanced/Metastatic Breast Or Non-Small Cell Lung Cancer (NSCLC)

Cancer Types: Breast Cancer, Lung Cancer
Lines of Therapy: 2nd Line Metastatic, 3rd Line + Metastatic
More details: https://clinicaltrials.gov/ct2/show/NCT04042701
Practices offering this clinical trial:

EC-120888 (LUN 437)

A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients With Completely Resected Stage I or IIA Non-squamous Non-Small Cell Lung Cancer Identified as High or Intermediate Risk by a 14-Gene Prognostic Assay

Cancer Types: Lung Cancer
Lines of Therapy: Adjuvant
More details: https://clinicaltrials.gov/ct2/show/NCT01817192
Practices offering this clinical trial:

EMN29

A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

Cancer Types: Hematology and Blood Disorders
Lines of Therapy: Other
More details: https://clinicaltrials.gov/study/NCT05028348
Practices offering this clinical trial:

EZH-302 (LYM 170) SYMPHONY-1

A Phase 1b/3 Double-blind, Randomized, Active-controlled, 3-stage, Biomarker Adaptive Study of Tazemetostat or Placebo in Combination With Lenalidomide Plus Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma

Cancer Types: Lymphoma
Lines of Therapy: 2nd Line Metastatic, Other
More details: https://clinicaltrials.gov/ct2/show/NCT04224493?term=EZH-302&draw=2&rank=1
Practices offering this clinical trial:

FID-007-003

Phase 2, Randomized, Multicenter, Open-label, Study of FID-007 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Cancer Types: Head and Neck Cancer
Lines of Therapy: 2nd Line Metastatic
More details: https://www.clinicaltrials.gov/study/NCT06332092
Practices offering this clinical trial:

FLM-6774-201 PEMDA-HN

An Open-Label, Phase II, Randomized, Controlled Study of Danvatirsen Plus Pembrolizumab Compared to Pembrolizumab Alone in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Cancer Types: Head and Neck Cancer
Lines of Therapy: 1st Line Metastatic and Locally Advanced
More details: https://clinicaltrials.gov/study/NCT05814666?term=flm-6774-201&rank=1
Practices offering this clinical trial:

GO42784 (BRE 386)

A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)

Cancer Types: Breast Cancer
Lines of Therapy: Adjuvant
More details: https://clinicaltrials.gov/study/NCT04961996?term=go42784&rank=1
Practices offering this clinical trial:

GS-US-595-6184 ASCENT-05

A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy

Cancer Types: Breast Cancer
Lines of Therapy: Adjuvant
More details: https://clinicaltrials.gov/study/NCT05633654
Practices offering this clinical trial:

GS-US-624-6376-03 (Velocity-Lung)

Phase 2 Platform Study Evaluating the Safety and Efficacy of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung)

Cancer Types: Lung Cancer
Lines of Therapy: Neo-Adjuvant
More details: https://clinicaltrials.gov/study/NCT05633667
Practices offering this clinical trial:

HH-PRT-0001 (TISSUE 32) CORE-HH

Cancer ORigin Epigenetics-Harbinger Health - Collection of Blood and Tissue Samples From Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test

Cancer Types: Solid Tumors, Supportive Care
Lines of Therapy: Other
More details: https://clinicaltrials.gov/ct2/show/NCT05435066?term=hh-prt-0001&draw=2&rank=1
Practices offering this clinical trial:

HLX10-005-SCLC301E ASTRIDE

A Randomized, Open-label Study of HLX10 plus Chemotherapy (CarboplatinEtoposide) in comparison with Atezolizumab plus Chemotherapy in Previously Untreated USPatients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) (ASTRIDE)

Cancer Types: Lung Cancer
Lines of Therapy: 1st Line Metastatic and Locally Advanced
More details: https://clinicaltrials.gov/study/NCT05468489
Practices offering this clinical trial:

HLX22-GC-301

Title A Randomized, Double-blinded, Multicenter, Phase Ⅲ Clinical Study of HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination with Trastuzumab and Chemotherapy (XELOX) Versus Trastuzumab and Chemotherapy (XELOX) with or without Pembrolizumab for the First Line Treatment of Locally Advanced or Metastatic Gastroesophageal Junction and Gastric Cancer

Cancer Types: Gastric
Lines of Therapy: 1st Line Metastatic and Locally Advanced
More details: https://clinicaltrials.gov/study/NCT06532006
Practices offering this clinical trial:

ID-VDP-103 (GI 324)

Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination with XELOX or Irinotecan in Patients with Advanced Gastric Cancer

Cancer Types: Gastric
Lines of Therapy: 1st Line Metastatic and Locally Advanced, 2nd Line Metastatic
More details: https://clinicaltrials.gov/study/NCT04725994?term=id-vdp-103&rank=1
Practices offering this clinical trial:

J2J-MC-JZLH (BRE 402) EMBER-4

A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence

Cancer Types: Breast Cancer
Lines of Therapy: Adjuvant
More details: https://clinicaltrials.gov/ct2/show/NCT05514054?term=j2j-mc-jzlh&draw=2&rank=1
Practices offering this clinical trial:

J3M-MC-JZQB SUNRAY-01

A Global Pivotal Study in Participants with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum regardless of PD-L1 Expression

Cancer Types: Lung Cancer
Lines of Therapy: 1st Line Metastatic and Locally Advanced
More details: https://clinicaltrials.gov/study/NCT06119581?term=j3m-mc-jzqb&rank=1
Practices offering this clinical trial:

JS004-008-III-SCLC JUSTAR

A Randomized, Double-Blind, Placebo-Controlled, Multi-Regional Phase III Clinical Study of Toripalimab Alone or in Combination With Tifcemalimab (JS004/TAB004) as Consolidation Therapy in Patients With Limited-Stage Small Cell Lung Cancer (LS-SCLC) Without Disease Progression Following Chemoradiotherapy

Cancer Types: Lung Cancer
Lines of Therapy: Other
More details: https://clinicaltrials.gov/study/NCT05353439?cond=Limited%20Stage%20Small%20Cell%20Lung%20Cancer&locStr=Bethesda,%20MD&country=United%20States&state=Maryland&city=Bethesda&aggFilters=status:rec&rank=1
Practices offering this clinical trial:

JZP598-303 (BRE 430)

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

Cancer Types: Breast Cancer
Lines of Therapy: 2nd Line Metastatic, 3rd Line + Metastatic
More details: https://clinicaltrials.gov/study/NCT06435429?term=jzp598-303&rank=1
Practices offering this clinical trial:

KRT-232-112 (LUN 469)

An Open-Label, Multicenter, Phase 2 Study of the Safety and Efficacy of KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer (SCLC)

Cancer Types: Lung Cancer
Lines of Therapy: 2nd Line Metastatic, 3rd Line + Metastatic
More details: https://clinicaltrials.gov/ct2/show/NCT05027867
Practices offering this clinical trial:

LOXO-BTK-2022 (CLL 51) BRUIN CLL-322

A Phase 3 Open-Label, Randomized Study of Fixed Duration LOXO-305 plus Venetoclax and Rituximab versus Venetoclax and Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)

Cancer Types: Leukemia
Lines of Therapy: Other
More details: https://clinicaltrials.gov/ct2/show/NCT04965493?term=NCT04965493&draw=2&rank=1
Practices offering this clinical trial:

M20-178 TRANSFORM-2

A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination With Ruxolitinib Versus Best Available Therapy in Subjects With Relapsed/Refractory Myelofibrosis

Cancer Types: Hematology and Blood Disorders
Lines of Therapy: Other
More details: https://clinicaltrials.gov/study/NCT04468984
Practices offering this clinical trial:

M20-621

A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab + R-CHOP versus R-CHOP alone in Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Cancer Types: Lymphoma
Lines of Therapy: Other
More details: https://classic.clinicaltrials.gov/ct2/show/NCT05578976?term=M20-621&cond=Diffuse+Large+B+Cell+Lymphoma&draw=2&rank=1
Practices offering this clinical trial:

M21-404

Phase 1 First in Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-400 as Monotherapy and in Combination With Bevacizumab in Adult Subjects With Advanced Solid Tumors

Cancer Types: Solid Tumors
Lines of Therapy: 2nd Line Metastatic
More details: https://www.clinicaltrials.gov/study/NCT05029882
Practices offering this clinical trial:

M21-406

First-in-Human Study of the BCL-2 Inhibitor ABBV-453 in Biomarker-Selected Subjects With Relapsed or Refractory Multiple Myeloma

Cancer Types: Hematology and Blood Disorders
Lines of Therapy: Other
More details: https://clinicaltrials.gov/study/NCT05308654?term=m21-406&rank=1
Practices offering this clinical trial:

M21-410

Global First-in-Human Study in NSCLC, HNSCC and Solid Tumors With ABBV-514 as a Single Agent and in Combination With Budigalimab

Cancer Types: Solid Tumors
Lines of Therapy: 2nd Line Metastatic
More details: https://clinicaltrials.gov/study/NCT05005403
Practices offering this clinical trial:

M22-003

A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) versus R2 alone versus Investigator’s Choice Chemoimmunotherapy in Untreated Follicular Lymphoma

Cancer Types: Lymphoma
Lines of Therapy: Other
More details: https://clinicaltrials.gov/study/NCT06191744?term=nct06191744&rank=1
Practices offering this clinical trial:

M23-324

A First-in-Human Study of ABBV-525 (MALT1 Inhibitor) in B-Cell Malignancies

Cancer Types: Lymphoma
Lines of Therapy: Other
More details: https://clinicaltrials.gov/study/NCT05618028
Practices offering this clinical trial:

M23-362

A Phase 2, Open-Label Trial to Evaluate Safety of Epcoritamab Monotherapy in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a) When Administered in the Outpatient Setting

Cancer Types: Lymphoma
Lines of Therapy: Other
More details: https://clinicaltrials.gov/study/NCT05451810?term=M23-362&rank=1
Practices offering this clinical trial:

M23-385

Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-706 as Monotherapy and in Combination With Budigalimab (ABBV-181), Carboplatin, or Cisplatin in Adult Subjects With Advanced Solid Tumors.

Cancer Types: Lung Cancer
Lines of Therapy: 2nd Line Metastatic
More details: https://clinicaltrials.gov/study/NCT05599984
Practices offering this clinical trial:

M23-721 LIVIGNO-4

Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer: Evaluation of the Optimal Dose, Safety, and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy – LIVIGNO-4

Cancer Types: Lung Cancer
Lines of Therapy: 1st Line Metastatic and Locally Advanced
More details: https://clinicaltrials.gov/study/NCT06236438
Practices offering this clinical trial:

M24-108

Phase 1b, Open-label Study to Evaluate Dose Optimization Measures and Safety of ABBV-383 in Subjects With Relapsed or Refractory Multiple Myeloma

Cancer Types: Multiple Myeloma
Lines of Therapy: 3rd Line + Metastatic
More details: https://www.clinicaltrials.gov/study/NCT05650632
Practices offering this clinical trial:

M24-287

A Prospective, Open-Label, Phase IIb/III Study to Evaluate the Risk of TLS and Optimization of the Initiation of Venetoclax in Combination with Obinutuzumab or Acalabrutinib With Different RampUp Periods in Previously Untreated Subjects with CLL

Cancer Types: Leukemia
Lines of Therapy: 1st Line Metastatic and Locally Advanced
More details:
Practices offering this clinical trial:

M24-311

Phase 2, Randomized Study to Evaluate Safety, Efficacy, and Optimal Dose of ABBV-400 in Combination With Fluorouracil, Folinic Acid, and Bevacizumab in Previously Treated Subjects With Unresectable Metastatic Colorectal Cancer

Cancer Types: Colon and Rectal Cancer
Lines of Therapy: 2nd Line Metastatic
More details: https://clinicaltrials.gov/study/NCT06107413
Practices offering this clinical trial:

MCLA-128-CL03

A Phase 2 Study Evaluating Activity of Zenocutuzumab (MCLA-128) in Patients With or Without Molecularly Defined Cancers

Cancer Types: Lung Cancer, Lymphoma
Lines of Therapy: 2nd Line Metastatic
More details: https://clinicaltrials.gov/study/NCT05588609
Practices offering this clinical trial:

ML43389 (LYM 196) MorningSun

An Open-Label, Multicenter, Phase II Trial Evaluating the Safety, Efficacy, and Pharmacokinetics of Subcutaneous Mosunetuzumab Monotherapy in Patients With Select B-Cell Malignancies

Cancer Types: Lymphoma
Lines of Therapy: 1st Line Metastatic and Locally Advanced, 2nd Line Metastatic
More details: https://clinicaltrials.gov/ct2/show/NCT05207670?term=ML43389&draw=2&rank=1
Practices offering this clinical trial:

ML45219 (BRAVE)

Phase II, Open-Label, Prospective Single-Arm, Multi-Center Clinical Trial to Evaluate if Adding Venetoclax to Patients on Covalent BTKi For 1L CLL Can Achieve Deep Durable Remissions (by UMRD 10^-4) to Allow Off-Treatment Period.

Cancer Types: Leukemia
Lines of Therapy: 1st Line Metastatic and Locally Advanced
More details: https://www.clinicaltrials.gov/study/NCT06524375
Practices offering this clinical trial:

NIT-119 (LUN 463)

A Multicenter, Open-label, Single-arm Phase II Study to Evaluate Anti-tumor Efficacy and Safety of NT-I7 in Combination With Atezolizumab in Subjects With Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC

Cancer Types: Lung Cancer
Lines of Therapy: 1st Line Metastatic and Locally Advanced
More details: https://clinicaltrials.gov/ct2/show/NCT04984811?term=NIT-119&draw=2&rank=1
Practices offering this clinical trial:

ONC-392-001 (MULTI 67) PRESERVE-001

Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)

Cancer Types: Lung Cancer, Solid Tumors
Lines of Therapy: 2nd Line Metastatic, 3rd Line + Metastatic
More details: https://clinicaltrials.gov/ct2/show/NCT04140526?term=ONC-392-001&draw=2&rank=1
Practices offering this clinical trial:

OP-1250-301 (BRE 416)

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer (OPERA-01)

Cancer Types: Breast Cancer
Lines of Therapy: 2nd Line Metastatic, 3rd Line + Metastatic
More details: https://clinicaltrials.gov/study/NCT06016738?term=op-1250-301&rank=1
Practices offering this clinical trial:

PM1183-C-008-21 (LUN 488) LAGOON

A Randomized, Multicenter, Open-label, Phase III Study of Lurbinectedin Single-Agent or Lurbinectedin in Combination With Irinotecan Versus Investigator's Choice (Topotecan or Irinotecan) in Relapsed Small Cell Lung Cancer Patients (LAGOON Trial)

Cancer Types: Lung Cancer
Lines of Therapy: 2nd Line Metastatic
More details: https://clinicaltrials.gov/study/NCT05153239?term=PM1183-C-008-21&rank=1
Practices offering this clinical trial:

PRESERVE-003 (LUN 514)

Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers That Progressed on PD-1/PD-L1 Inhibitors

Cancer Types: Lung Cancer
Lines of Therapy: 2nd Line Metastatic
More details: https://classic.clinicaltrials.gov/ct2/show/NCT05671510?term=Phase+3%2C+Two-stage%2C+Randomized+Study+of+ONC-392+Versus+Docetaxel+in+Metastatic+Non-Small+Cell+Lung+Cancers+that+Progressed+on+PD-1%2FPD-L1+Inhibitors&draw=2&rank=1
Practices offering this clinical trial:

PRL-02-1001

Phase 1, Open-Label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer

Cancer Types: Prostate Cancer
Lines of Therapy: 2nd Line Metastatic
More details: https://www.clinicaltrials.gov/study/NCT04729114
Practices offering this clinical trial:

PRT2527-02

A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib in Participants With Relapsed/Refractory Hematologic Malignancies

Cancer Types: Lymphoma
Lines of Therapy: Other
More details: https://clinicaltrials.gov/study/NCT05665530
Practices offering this clinical trial:

PTG-300-11 VERIFY

A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients With Polycythemia Vera

Cancer Types: Hematology and Blood Disorders
Lines of Therapy: Other
More details: https://clinicaltrials.gov/study/NCT05210790
Practices offering this clinical trial:

PUMA-ALI-1201

A PHASE 2 STUDY OF ALISERTIB IN COMBINATION WITH ENDOCRINE THERAPY IN PATIENTS WITH HR+, HER2-NEGATIVE RECURRENT OR METASTATIC BREAST CANCER

Cancer Types: Breast Cancer
Lines of Therapy: 3rd Line + Metastatic
More details: https://clinicaltrials.gov/study/NCT06369285?term=puma-ali-1201&rank=1
Practices offering this clinical trial:

R3767-ONC-22122

Phase 3 Study of Fixed Dose Combinations of Fianlimab and Cemiplimab Versus Relatlimab and Nivolumab in Participants With Unresectable or Metastatic Melanoma

Cancer Types: Melanoma
Lines of Therapy: 1st Line Metastatic and Locally Advanced
More details: https://clinicaltrials.gov/study/NCT06246916
Practices offering this clinical trial:

RBS2418-1001

A First-In-Human, Phase 1 a/b Dose Escalation and Expansion Study to Evaluate RBS2418 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Unresectable, Recurrent or Metastatic Tumors

Cancer Types: Biliary Cancer, Bladder Cancer, Brain Cancer, Colon and Rectal Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, Melanoma, Ovarian and Endometrial Cancer, Prostate Cancer, Pancreatic Cancer
Lines of Therapy: Other
More details: https://clinicaltrials.gov/study/NCT05270213
Practices offering this clinical trial:

RMC-4630-03 (LUN 468)

A Phase 2, Open-Label, Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies

Cancer Types: Lung Cancer
Lines of Therapy: 1st Line Metastatic and Locally Advanced, 2nd Line Metastatic, 3rd Line + Metastatic
More details: https://clinicaltrials.gov/ct2/show/NCT05054725
Practices offering this clinical trial:

RMC-6291-001

Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

S1823

A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients With Newly Diagnosed Germ Cell Tumors

Cancer Types: Testicular
Lines of Therapy: Other
More details: https://clinicaltrials.gov/ct2/show/NCT04435756
Practices offering this clinical trial:

S1914

A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC

Cancer Types: Lung Cancer
Lines of Therapy: 1st Line Metastatic and Locally Advanced
More details: https://clinicaltrials.gov/ct2/show/NCT04214262?term=s1914&draw=2&rank=1
Practices offering this clinical trial:

SGNB6A-001

Phase 1 Study of SGN-B6A in Advanced Solid Tumors

Cancer Types: Lung Cancer, Head and Neck Cancer
Lines of Therapy: 1st Line Metastatic and Locally Advanced, 2nd Line Metastatic, 3rd Line + Metastatic
More details: https://www.clinicaltrials.gov/study/NCT04389632
Practices offering this clinical trial:

SGNB6A-002 Be6A Lung-01

A randomized, phase 3, open-label study to evaluate sigvotatug vedotin compared with docetaxel in adult participants with previously treated non-small cell lung cancer (Be6A Lung-01)

Cancer Types: Lung Cancer
Lines of Therapy: 1st Line Metastatic and Locally Advanced, 2nd Line Metastatic
More details: https://my.clevelandclinic.org/clinical-trials/2058-a-randomized-phase-3-open-label-study-to-evaluate-sigvotatug-vedotin-compared-with-docetaxel-in-adult-participants-with-previously-treated-non-small-cell-lung-cancer-be6a-lung-01
Practices offering this clinical trial:

SY-1425-301 SELECT MDS-1

A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome (SELECT MDS-1)

Cancer Types: Hematology and Blood Disorders
Lines of Therapy: Other
More details: https://clinicaltrials.gov/study/NCT04797780
Practices offering this clinical trial:

TP-CA-002

TEMPUS GEMINI NSCLC SURVEILLANCE STUDY: A Longitudinal Multi-Omic Biomarker Profiling Study of Patients with Non-Small Cell Lung Cancer (NSCLC)

Cancer Types: Lung Cancer
Lines of Therapy: Neo-Adjuvant, 1st Line Metastatic and Locally Advanced
More details: https://clinicaltrials.gov/study/NCT05236114?term=TP-CA-002&rank=1
Practices offering this clinical trial:

TP-CA-005

Umbrella Study for Analysis of Data Related to Patients With Cancer

Cancer Types: Solid Tumors
Lines of Therapy: Other
More details: https://clinicaltrials.gov/study/NCT06018753?term=tp-ca-005&rank=1
Practices offering this clinical trial:

TP-CA-006 PHOENIX

Longitudinal Multi-Omic Biomarker Profiling Study of Patients with Head & Neck Squamous Cell Carcinoma (HNSCC)

Cancer Types: Head and Neck Cancer, Supportive Care
Lines of Therapy: Other
More details: https://clinicaltrials.gov/study/NCT06163534?term=tp-ca-006&rank=1
Practices offering this clinical trial:

TP-CA-007

TEMPUS ARIES: A Biobank Registry Platform Study in Oncology

Cancer Types: Colon and Rectal Cancer, Lung Cancer, Pancreatic Cancer
Lines of Therapy: Other
More details: https://clinicaltrials.gov/study/NCT06207032?term=tp-ca-007&rank=1
Practices offering this clinical trial:

TSC-007 PRECISION 1

A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes.

Cancer Types: Biliary Cancer, Bladder Cancer, Brain Cancer, Breast Cancer, Colon and Rectal Cancer, Kidney Cancer, Liver Cancer, Melanoma, Ovarian and Endometrial Cancer, Prostate Cancer
Lines of Therapy: Other
More details: https://clinicaltrials.gov/study/NCT05103358
Practices offering this clinical trial:

TT420C2308 (GI 356)

Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma (FIRST-308)

Cancer Types: Biliary Cancer
Lines of Therapy: 2nd Line Metastatic, 3rd Line + Metastatic
More details: https://clinicaltrials.gov/study/NCT05948475?term=NCT05948475&rank=1
Practices offering this clinical trial:

TTX-030-003 (GI 361)

An Open-Label Multicenter 3-Arm Randomized Phase 2 Study to Assess the Efficacy and Safety of TTX-030 and Chemotherapy With or Without Budigalimab, Compared to Chemotherapy Alone, for the Treatment of Patients not Previously Treated for Metastatic Pancreatic Adenocarcinoma

Cancer Types: Pancreatic Cancer
Lines of Therapy: 1st Line Metastatic and Locally Advanced
More details: https://classic.clinicaltrials.gov/ct2/show/NCT06119217
Practices offering this clinical trial:

TTX-030-003 (GI 361)

Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients

Cancer Types: Pancreatic Cancer
Lines of Therapy: 1st Line Metastatic and Locally Advanced
More details: https://clinicaltrials.gov/study/NCT06119217?term=ttx-030-003&rank=1
Practices offering this clinical trial:

XPORT-EC-042 (GYN 117)

A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Cancer Types: Ovarian and Endometrial Cancer
Lines of Therapy: 2nd Line Metastatic
More details: https://clinicaltrials.gov/study/NCT05611931?term=XPORT-EC-042&rank=1
Practices offering this clinical trial:

ZEN003694-201 (GU 200)

A Randomized Phase 2b Study of ZEN003694 in Combination With Enzalutamide Versus Enzalutamide Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Cancer Types: Prostate Cancer
Lines of Therapy: 1st Line Metastatic and Locally Advanced
More details: https://clinicaltrials.gov/ct2/show/NCT04986423?term=ZEN003694-201&draw=2&rank=1
Practices offering this clinical trial:

Zn-c3-005 (GYN 45) DENALI

A Phase 2 Open-Label, Multicenter Study To Evaluate Efficacy And Safety Of ZN-c3 In Subjects With High-Grade Serous Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer